The corresponding PDXs mirrored patient tumor sensitivity to anti-EGFR treatment, and the tumor response of PDX_489 and PDX_545 were mCR (−100.00%) and mPD (352.76%) (Fig. 1f–i), respectively. This evidence concerns the gene EGFR and neoplasm.